In Brief: Oncologic Drugs Advisory Committee
Executive Summary
Oncologic Drugs Advisory Committee: Janssen's Liazal (liarozole fumarate, NDA 27-094) will be reviewed the morning of June 24 for treatment of advanced prostate cancer. On June 23, committee will consider Ilex' Zyrkamine (mitoguazone, NDA 20-709) for treatment of AIDS-related non-Hodgkin's lymphoma and Bristol-Myers Squibb's Taxol (paclitaxel, NDA 20-262) for second-line treatment of AIDS-related Kaposi's sarcoma. The meeting will take place at the Holiday Inn-Bethesda, Md. beginning 8:30 a.m. on June 23 and 9 a.m. June 24...